Results 51 to 60 of about 1,506 (115)

Synthesis, X‐Ray Analysis, Anticancer Activity, Computational, and in Silico Studies of New Thiophene Pyrazole Conjugates

ChemistryOpen, Volume 15, Issue 6, June 2026.
Two new thiophene–pyrazole derivatives, 8a and 8b, were synthesized from thiophene 3 precursor and fully characterized. The structure of 8a was confirmed by single‐crystal X‐ray diffraction, which revealed a nonplanar conformation stabilized by NH···O hydrogen bonding and weak intermolecular contacts.
Abdullatif Bin Muhsinah, Nabila A. Kheder, Ismail A. Elhaty, Yahia N. Mabkhot   +3 more
wiley   +1 more source

RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report

Heliyon
Patients with non-small cell lung cancer (NSCLC) and anaplastic lymphoma kinase (ALK) mutations have previously derived substantial benefits from ALK tyrosine kinase inhibitors (ALK-TKIs). However, resistance may develop in some patients.
Huan Yan, Liang Zeng, Yongchang Zhang
doaj   +1 more source

Challenges in Implementing Revocation of Oncology Drugs Under Conditional Early Approval in Japan: Regulatory Insights From Comparisons With FDA/EMA

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Expedited pathways in the United States (U.S.), European Union (EU), and Japan (JP) enable earlier access to innovative therapies for rare and serious diseases. In 2025, Japan explicitly introduced revocation provisions to its Conditional Early Approval (CEA).
Takahiro Handa, Arata Tanaka, Mayumi Shikano, Rika Wakao   +3 more
wiley   +1 more source

Brain Metastases From Differentiated Thyroid Cancer in the Era of Targeted Therapies: A Multi‐Center Retrospective Cohort

Head &Neck, Volume 48, Issue 5, Page 1332-1339, May 2026.
ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel, Shaun Edalati, Eyal Yosefof, Anton Warshavsky, Gilad Horowitz, Nidal Muhanna, Hagit Shoffel‐Havakuk, Eyal Robenshtok, Aron Popovtzer, Inbar Finkel   +9 more
wiley   +1 more source

A real−world pharmacovigilance study of FDA Adverse Event Reporting System events for pralsetinib

Frontiers in Oncology
BackgroundPralsetinib, a selective oral inhibitor of rearranged during transfection (RET) fusion proteins and oncogenic RET mutants, has shown significant efficacy in treating RET fusion-positive non-small cell lung cancer and thyroid cancer.
Yi Yin, Fengli Sun, Youpeng Jin
doaj   +1 more source

Therapeutic strategies in RET gene rearranged non-small cell lung cancer

Journal of Hematology & Oncology, 2021
The recent approvals by the Food and Drug Administration several tumor-agnostic drugs have resulted in a paradigm shift in cancer treatment from an organ/histology-specific strategy to biomarker-guided approaches.
Leylah M. Drusbosky, Estelamari Rodriguez, Richa Dawar, Chukwuemeka V. Ikpeazu   +3 more
doaj   +1 more source

Systematic Proteomic Characterization of EV‐A71‐Infected Mice Identifies Dynamic Molecular Changes and Therapeutic Targets

MedComm, Volume 7, Issue 4, April 2026.
Time‐resolved multi‐omics of EV‐A71‐infected BALB/c mice uncovered dynamic host responses, revealing rapid neutrophil extracellular traps (NETs) activation as a key event. Screened drugs (kinase inhibitors) suppressed viral replication in vitro and in vivo, suggesting the promise of targeting host phosphorylation networks as a viable antiviral strategy.
Wanjun Peng, Qiaochu Wang, Binbin Zhao, Lihong Zhang, Jing Wu, Xiaohui Wei, Na Rong, Zhaohua Wang, Kaihui Liu, Jiangfeng Liu, Juntao Yang, Jiangning Liu   +11 more
wiley   +1 more source

Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC)

BMC Pulmonary Medicine
Objective The present study endeavors to furnish an exhaustive review of the research advancements on solid tumors harboring RET rearrangement within the Chinese context, particularly emphasizing the examination of real-world therapeutic strategies and ...
An Wang, Tao Li, Yun-ye Mao, Ming Gao, Sheng Shu, Chang-hong Xia, Yi Dong, Min Liu, Jin-liang Wang, Jun-xun Ma, Yi Hu   +10 more
doaj   +1 more source

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

JTO Clinical and Research Reports
RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case ...
Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD   +2 more
doaj   +1 more source

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report

Cancer Management and Research, 2023
Hao Qin,1,* Yuxiang Wan,2,* Yuchao Dong,1 Qinying Sun1 1Department of Respiratory and Critical Care Medicine, Shanghai Changhai Hospital, The First Affiliated Hospital of Second Military Medical University, Shanghai, People’s Republic of China ...
Qin H, Wan Y, Dong Y, Sun Q
doaj